To improve the lives of patients with severe inflammatory diseases and cancer
Now patients may be selected for treatment with Bertilimumab based on the levels of eotaxin-1, a biomarker of disease severity and a regulator of gastro-intestinal inflammation
Learn more about Bertilimumab clinical development for Crohn’s and Colitis.
TAKING A PERSONALIZED APPROACH TO CROHN’s and COLITIS
BRINGING NEW HOPE FOR OLDERS PATIENTS WITH BULLOUS PHEMPHIGOID
Bertilimumab targets eotaxin-1, a pro-inflammatory protein found in the skin of patients with Bullous Pemphigoid (BP), a rare auto-immune disease.
Learn more about Bertilimumab clinical development for BP.
DEVELOPING A NOVEL TOPICAL OPTION TO RELIEVE NEUROPATHIC PAIN
Anyone of the available drugs for the Neuropathic pain is either not effective or poorly tolerated by up to 50% patients suffering from Neuropathic pain.
Learn more about Amiket a novel local treatment in advanced clinical development for Neuropathic pain.